Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck

BMC Cancer

Volumn 13, Issue 1, 2013, Pages

  Bae, Woo Kyun ^a   Hwang, Jun Eul ^a   Shim, Hyun Jeong ^a   Cho, Sang Hee ^a,f   Lee, Ki Hyeong ^b   Han, Hye Suk ^b   Song, Eun Kee ^c   Yun, Hwan Jung ^d   Cho, In Sung ^e   Lee, Joon Kyoo ^a   Lim, Sang Chul ^a   Chung, Woong Ki ^a   Chung, Ik Joo ^a  

^a Chonnam National University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Chonbuk National University   (South Korea)

^d Chungnam National University   (South Korea)

^e Eulji University   (South Korea)

^f Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

Cisplatin based regimen containing S 1; Head and neck squamous cell carcinoma; Induction chemotherapy; Weekly docetaxel

Indexed keywords

CISPLATIN; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; OTERACIL; S 1 (COMBINATION); TAXOID; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOPHARYNX SQUAMOUS CELL CARCINOMA; KIDNEY DISEASE; LARYNX SQUAMOUS CELL CARCINOMA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; ODYNOPHAGIA; OROPHARYNX SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DRUG COMBINATION; HEAD AND NECK TUMOR; INDUCTION CHEMOTHERAPY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DRUG COMBINATIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; OXONIC ACID; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS; TEGAFUR;

EID: 84874514938     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-102     Document Type: Article

References (38)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10-30
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Head and neck cancer. N Engl J Med 1993, 328(3):184-194
3. Munro AJ: An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995, 71(1):83-91
4. El-Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996, 14(3):838-847
5. Rinehart J, Ruff T, Cheung A, Hutchinson L, Tuggle R, Pinkston DR, Keville L, Wong L: Neoadjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma. Otolaryngol Head Neck Surg 2005, 132(1):69-74
6. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994, 86(4):265-272
7. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996, 88(13):890-899
8. Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R: Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol 2005, 28(4):371-378
9. Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado RM, Wood BG, Strome M, Carroll MA: Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002, 20(5):1405-1410
10. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advancedstage oropharynx carcinoma. J Clin Oncol 2004, 22(1):69-76
11. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB: Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004, 31(6):778-785
12. Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE: Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 1987, 60(6):1178-1183
13. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355(9208):949-955
14. Hitt R, Paz-Ares L, Brandariz A, Castellano D, Pena C, Millan JM, Calvo F, Ortiz De Urbina D, Lopez E, Alvarez-Vicent JJ, et al: Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol 2002, 13(10):1665-1673
15. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA: Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001, 19(4):1096-1104
16. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357(17):1695-1704
17. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357(17):1705-1715
18. Ahn JS, Cho SH, Kim OK, Lee JK, Yang DH, KimYK, Lee JJ, LimSC, KimHJ, Chung WK, et al: The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer. Cancer Res Treat 2007, 39(3):93-98
19. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P, et al: Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005, 16(1):90-96
20. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, Gonzalez JL, Almenar D, Blasco A, Rosell R, et al: Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006, 17(3):467-472
21. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, et al: Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005, 23(33):8389-8395
22. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7(5):548-557
23. Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, Liossi P, Giannakouras G, Douzinas EE, Katsilieris I: Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol 2006, 42(7):675-684
24. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007, 18(10):1673-1679
25. Chun JH, Kim HK, Lee JS, Choi JY, Hwangbo B, Lee HG, Park SR, Choi IJ, Kim CG, Ryu KW, et al: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005, 28(2):188-194
26. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, et al: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000, 18(6):1212-1219
27. Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM: Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol 2007, 105(2):358-364
28. Bria E, Cuppone F, Ciccarese M, Nistico C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F, Giannarelli D: Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 2006, 32(8):583-587
29. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B: Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group). Gan To Kagaku Ryoho 1998, 25(8):1151-1158
30. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B: Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001, 28(10):1381-1390
31. Fujii M, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, Yamane H, Homma A, Tomita T: Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn J Clin Oncol 2010, 40(3):214-221
32. Choi YJ, Chung JS, Shin HJ, Cho GJ, Wang SG, Lee BJ, Cho BM, Joo YD, Sohn CH: Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. J Laryngol Otol 2008, 122(8):848-853
33. Nakayama N, Koizumi W, Sasaki T, Higuchi K, Tanabe S, Nishimura K, Katada C, Nakatani K, Takagi S, Saigenji K: A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 2008, 75(1-2):1-7
34. Takayama T, Sato Y, Sagawa T, Okamoto T, Nagashima H, Takahashi Y, Ohnuma H, Kuroiwa G, Miyanishi K, Takimoto R, et al: Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 2007, 97(7):851-856
35. Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T: Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs 2009, 20(8):752-756
36. Wirth LJ, Posner MR: Recent advances in combined modality therapy for locally advanced head and neck cancer. Curr Cancer Drug Targets 2007, 7(7):674-680
37. Tahara M, Araki K, Okano S, Kiyota N, Fuse N, Minashi K, Yoshino T, Doi T, Zenda S, Kawashima M, et al: Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer. Ann Oncol 2011, 22(1):175-180
38. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350(19):1937-1944